uniQure CEO Vows To Finish Huntington's Trial Even If FDA Rejects Its Gene Therapy

CEO Matt Kapusta calls the study an ethical obligation, with an FDA decision on AMT-130 targeted for May 1, 2027.

Share
uniQure CEO Vows To Finish Huntington's Trial Even If FDA Rejects Its Gene Therapy

uniQure will complete its confirmatory Huntington's disease study whether or not the FDA approves its gene therapy AMT-130, CEO Matt Kapusta said on the company's third-quarter earnings call on Wednesday. The FDA's target decision date is May 1, 2027.

uniQure develops one-time gene therapies for rare and serious diseases; its Huntington's candidate is AMT-130. Asked by an analyst from UBS whether a rejection would still bind it to the study, Kapusta said, "I don't know if it's a legal obligation," but described an ethical obligation to the Huntington's community and said the company is committed to finishing the study "whether or not the drug is approved."

If the drug is not approved on the target date, he said, the company would have to understand "the reasons why and what our next steps are going to be."

Chief Medical Officer Dr. Walid Abi-Saab said the study will randomize about 200 patients, 2-to-1, to high-dose AMT-130 versus standard of care. The main goal is total functional capacity at 36 months, and screening is expected to begin by the end of this year. The protocol has been submitted to review boards in the U.S., and sites will span North America, Europe and Latin America. Standard-of-care patients will be offered AMT-130 in a separate open-label study after 36 months.

What "well underway" means

An analyst from William Blair asked how the FDA defines a confirmatory study that is "well underway" at the time of accelerated approval. Kapusta said the agency has "wide discretion," knows the study is just starting and has been given approximate timelines. uniQure will first enroll in U.S. centers already running, he said.

Abi-Saab said uniQure will submit a day-120 safety update and would announce any FDA request for four-year data that triggered a delay to the decision date. Otherwise, he said, the company will not comment on information requests during the review.

Launch capacity, not demand

Asked how many patients could be treated at launch, Chief Customer and Strategy Officer Kylie O'Keefe said it was "a bit premature to provide specific patient estimates." She said the company expects early uptake to be limited by treatment-center capacity rather than demand, and that launch capacity will be "north of 15 centers," possibly 25 or 30. There are more than 60 Huntington's Disease Society of America centers of excellence in the U.S., she said, rising to north of 100 with centers that have ClearPoint capability. Kapusta said manufacturing should not be a constraint.

The company reported third-quarter revenue of $5.2 million, versus $3.7 million a year earlier. Research spending was $35.5 million and selling, general and administrative costs $23.9 million, versus $19.4 million. Cash and investments totaled $768.4 million at September 30, which the company expects to fund operations into 2030. Its market value was about $1.7 billion.

uniQure expects to begin screening patients for the confirmatory study by year-end, ahead of the May 1, 2027 decision date.

Sources

More on uniQure

All uniQure (QURE) coverage →